Accurate detection of drug-induced delayed ventricular repolarization with a suitable correction formula in Langendorff guinea pig heart

Journal of Toxicological Sciences

Volumn 35, Issue 5, 2010, Pages 687-698

  Tabo, Mitsuyasu ^a   Komatsu, Ryuichi ^a   Isobe, Takehito ^a   Honda, Masaki ^a   Yamada, Yuichiro ^a   Kimura, Kazuya ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Exponential rate correction; Isolated perfused guinea pig heart; Langendorff; Moxifloxacin; QT interval prolongation

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; MOXIFLOXACIN; VERAPAMIL; ZATEBRADINE;

ACTION POTENTIAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATRIOVENTRICULAR DISSOCIATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SENSITIVITY; ELECTROCARDIOGRAM; GUINEA PIG; HEART ATRIUM PACING; HEART ELECTROPHYSIOLOGY; HEART RATE; HEART REPOLARIZATION; ISOLATED HEART; LINEAR REGRESSION ANALYSIS; MALE; NONHUMAN; OUTCOME ASSESSMENT; QT INTERVAL; QT PROLONGATION; RELIABILITY; RR INTERVAL;

CAVIA;

EID: 77958051729     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.35.687     Document Type: Article

References (43)

1. Akaike, H. (1974): A new look at the statistical model identification. IEEE Trans. Automat. Cont., AC-19, 716-723.
2. Balfour, J.A.B. and Wiseman, L.R. (1999): Moxifloxacin. Drugs, 57, 363-373.
3. Bazett, H.C. (1920): An analysis of the time-relations of electrocardiograms. Heart, 7, 353-370.
4. Cavero, I., Mestre, M., Guillon, J.M., Heuillet, E. and Roach, A.G. (1999): Preclinical in vitro cardiac electrophysiology: A method of predicting arrhythmogenic potential of antihistamines in humans? Drug Saf., 21, Suppl. 1, 19-31. (Pubitemid 30000236)
5. Chaves, A.A., Keller, W.J., O'Sullivan, S., Williams, M.A., Fitzgerald, L.E., McPherson, H.E., Goykhman, D., Ward, P.D., Hoe, C.M., Mixson, L. and Briscoe, R.J. (2006): Cardiovascular monkey telemetry: Sensitivity to detect QT interval prolongation. J. Pharmacol. Toxicol. Methods, 54, 150-158.
6. Chen, X., Cass, J.D., Bradley, J.A., Dahm, C.M., Sun, Z., Kadyszewski, E., Engwall, M.J. and Zhou, J. (2005). QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome. Br. J. Pharmacol., 146, 792-799.
7. Cheng, H.C., Incardona, J. and McCullough, B. (2006): Isolated perfused and paced guinea pig heart to test for drug-induced changes of the QT interval. J. Pharmacol. Toxicol. Methods, 54, 278-287.
8. De Ponti, F., Poluzzi, E. and Montanaro, N. (2001): Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus. Eur. J. Clin. Pharmacol., 57, 185-209.
9. Démolis, J.-L., Kubitza, D., Tennezé, L. and Funck-Brentano, C. (2000): Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin. Pharmacol. Ther., 68, 658-666.
10. Franke, H., Su, C.A.P.F., Schumacher, K. and Seiberling, M. (1987): Clinical pharmacology of two specific bradycardiac agents. Eur. Heart J., 8, 91-98.
11. Fridericia, L.S. (1920): Die systolendauer im elektrokardiogramm bei normalen menschen und bei herzkranken. Acta Med. Scand., 53, 469-486.
12. Gonzalez-Gomez, A., Cires Pujols, M., Gamio Capestany, F., Rodriguez de la Vega, A. and Garcia-Barreto, D. (1988): Relationships between verapamil plasma concentrations and its antihypertensive action. Int. J. Clin. Pharmacol. Ther. Toxicol., 26, 453-460.
13. Guo, L., Dong, Z. and Guthrie, H. (2009): Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates. J. Pharmacol. Toxicol. Methods, 60, 130-151.
14. Guth, B.D., Germeyer, S., Kolb, W. and Markert, M. (2004): Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization. J. Pharmacol. Toxicol. Methods, 49, 159-169.
15. Hamlin, R.L., Kijtawornrat, A., Keene, B.W. and Hamlin, D.M. (2003a): QT and RR intervals in conscious and anesthetized guinea pigs with highly varying RR intervals and given QTc-lengthening test articles. Toxicol. Sci., 76, 437-442.
16. Hamlin, R.L., Nakayama, T., Nakayama, H. and Carnes, C.A. (2003b): Effects of changing heart rate on electrophysiological and hemodynamic function in the dog. Life Sci., 72, 1919-1930. (Pubitemid 36207529)
17. Hamlin, R.L., Cruze, C.A., Mittelstadt, S.W., Kijtawornrat, A., Keene, B.W., Roche, B.M., Nakayama, T., Nakayama, H., Hamlin, D.M. and Arnold, T. (2004): Sensitivity and specificity of isolated perfused guinea pig heart to test for drug-induced lengthening of QTc. J. Pharmacol. Toxicol. Methods, 49, 15-23.
18. Harada, T., Abe, J., Shiotani, M., Hamada, Y. and Horii, I. (2005): Effect of autonomic nervous function on QT interval in dogs. J. Toxicol. Sci., 30, 229-237.
19. Hauser, D.S., Stade, M., Schmidt, A. and Hanauer, G. (2005): Cardiovascular parameters in anaesthetized guinea pigs: A safety pharmacology screening model. J. Pharmacol. Toxicol. Methods, 52, 106-114.
20. Holzgrefe, H.H., Cavero, I., Buchanan, L.V., Gill, M.W. and Durham, S.K. (2007): Application of a probabilistic method for the determination of drug-induced QT prolongation in telemetered cynomolgus monkeys: Effects of moxifloxacin. J. Pharmacol. Toxicol. Methods, 55, 244-254.
21. ICH Harmonised Tripartite Guideline, The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs (E14). ICH; http://www.ich.org/.
22. Kakusaka, S., Asayama, M., Kaihara, A., Sasano, T., Suzuki, T., Kurokawa, J. and Furukawa, T. (2009): A receptor-independent effect of estrone sulfate on the hERG channel. J. Pharmacol. Sci., 109, 152-156.
23. Kirsch, G.E., Trepakova, E.S., Brimecombe, J.C., Sidach, S.S., Erickson, H.D., Kochan, M.C., Shyjka, L.M., Lacerda, A.E. and Brown, A.M. (2004): Variability in the measurement of hERG potassium channel inhibition: Effects of temperature and stimulus pattern. J. Pharmacol. Toxicol. Methods, 50, 93-101.
24. Kobinger, W. and Lillie, C. (1984): Cardiovascular characterization of UL-FS 49,1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-[[2-(3,4-dimethoxyphenyl)ethyl] methylimino]propyl]-2H-3-benzazepin-2-on hydrochloride, a new "specific bradycardic agent". Eur. J. Pharmacol., 104, 9-18.
25. Komatsu, R., Honda, M., Holzgrefe, H.H., Kubo, J., Yamada, Y., Isobe, T., Kimura, K., Itoh, T., Tamaoki, N. and Tabo, M. (2010): Sensitivity of common marmosets to detect drug-induced QT interval prolongation: Moxifloxacin case study. J. Pharmacol. Toxicol. Methods, 61, 271-276.
26. Kr channels and drug-induced prolongation of cardiac repolarization. J. Physiol., 586, 2961-2973.
27. Lacroix, P., Crumb, W.J., Durando, L. and Ciottoli, G.B. (2003): Prulifloxacin: in vitro (HERG current) and in vivo (conscious dog) assessment of cardiac risk. Eur. J. Pharmacol., 477, 69-72.
28. Matsunaga, T., Mitsui, T., Harada, T., Inokuma, M., Murano, H. and Shibutani, Y. (1997): QT corrected for heart rate and relation between QT and RR intervals in beagle dogs. J. Pharmacol. Toxicol. Methods, 38, 201-209.
29. Nakamura, H., Kurokawa, J., Bai, C.-X., Asada, K., Xu, J., Oren, R.V., Zhu, Z.I., Clancy, C.E., Isobe, M. and Furukawa, T. (2007): Progesterone regulates cardiac repolarization through a nongenomic pathway: An in vitro patch-clamp and computational modeling study. Circulation, 116, 2913-2922.
30. Omata, T., Kasai, C., Hashimoto, M., Hombo, T. and Yamamoto, K. (2005): QT PRODACT: Comparison of non-clinical studies for drug-induced delay in ventricular repolarization and their role in safety evaluation in humans. J. Pharmacol. Sci., 99, 531-541.
31. Redfern, W.S., Carlsson, L., Davis, A.S., Lynch, W.G., MacKenzie, I., Palethorpe, S., Siegl, P.K.S., Strang, I., Sullivan, A.T., Wallis, R., Camm, A.J. and Hammond, T.G. (2003): Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res., 58, 32-45.
32. Sarma, J.S.M., Sarma, R.J., Bilitch, M., Katz, D. and Song, S.L. (1984): An exponential formula for heart rate dependence of QT interval during exercise and cardiac pacing in humans: Reevaluation of Bazett's formula. Am. J. Cardiol., 54, 103-108.
33. Shah, R.R. (2005): Drugs, QT interval prolongation and ICH E14: The need to get it right. Drug Saf., 28, 115-125.
34. Stubhan, M., Markert, M., Mayer, K., Trautmann, T., Klumpp, A., Henke, J. and Guth, B. (2008): Evaluation of cardiovascular and ECG parameters in the normal, freely moving Gottingen Minipig. J. Pharmacol. Toxicol. Methods, 57, 202-211.
35. Tabo, M., Nakamura, M., Kimura, K. and Ito, S. (2006): QT-RR relationships and suitable QT correction formulas for halothane-anesthetized dogs. J. Toxicol. Sci., 31, 381-390.
36. Tabo, M., Kimura, K. and Ito, S. (2007): Monophasic action potential in anaesthetized guinea pigs as a biomarker for prediction of liability for drug-induced delayed ventricular repolarization. J. Pharmacol. Toxicol. Methods, 55, 271-278.
37. Tabo, M., Hara, T., Sone, S., Shishido, N., Kuramoto, S., Nakano, K., Onodera, H., Kimura, K. and Kobayashi, K. (2008a): Prediction of drug-induced QT interval prolongation in telemetered common marmosets. J. Toxicol. Sci., 33, 315-325.
38. Tabo, M., Komatsu, R., Honda, M., Itoh, M. and Kimura, K. (2008b): Cardiovascular safety profile of MA-2029, a novel motilin receptor antagonist. J. Toxicol. Sci., 33, 631-639.
39. Takahara, A., Sugiyama, A. and Hashimoto, K. (2005): Reduction of repolarization reserve by halothane anaesthesia sensitizes the guinea-pig heart for drug-induced QT interval prolongation. Br. J. Pharmacol., 146, 561-567.
40. Testai, L., Calderone, V., Salvadori, A., Breschi, M.C., Nieri, P. and Martinotti, E. (2004): QT prolongation in anaesthetized guinea-pigs: an experimental approach for preliminary screening of torsadogenicity of drugs and drug candidates. J. Appl. Toxicol., 24, 217-222.
41. Webster, R., Leishman, D. and Walker, D. (2002): Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr. Opin. Drug Discov. Devel., 5, 116-126.
42. Zhang, S., Zhou, Z., Gong, Q., Makielski, J.C. and January, C.T. (1999): Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ. Res., 84, 989-998.
43. Zhou, Z., Gong, Q., Ye, B., Fan, Z., Makielski, J.C., Robertson, G.A. and January, C.T. (1998): Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys. J., 74, 230-241.